



FLORE

Repository istituzionale dell'Università degli Studi di Firenze

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma / Lepletier A.; Madore J.; O'Donnell J.S.; Johnston R.L.; Li X.-Y.; McDonald E.; Ahern E.; Kuchel A.; Eastgate M.; Pearson S.-A.; Mallardo D.; Ascierto P.A.; Massi D.; Merelli B.; Mandala M.; Wilmott J.S.; Menzies A.M.; Leduc C.; Stagg J.; Routy B.; Long G.V.; Scolyer R.A.; Bald T.; Waddell N.; Dougall W.C.; Teng M.W.L.; Smyth M.J.. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - ELETTRONICO. - 26:

Availability:

This version is available at: 2158/1213223 since: 2020-10-23T10:46:29Z

Published version: DOI: 10.1158/1078-0432.CCR-19-3925

Terms of use: Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)

Publisher copyright claim:

Conformità alle politiche dell'editore / Compliance to publisher's policies

Questa versione della pubblicazione è conforme a quanto richiesto dalle politiche dell'editore in materia di copyright.

This version of the publication conforms to the publisher's copyright policies.

(Article begins on next page)

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

Ailin Lepletier^{1#}, Jason Madore^{1#}, Jake S. O'Donnell^{1,2,3}, Rebecca L. Johnston⁴, Xian-Yang Li¹, Elizabeth McDonald², Elizabeth Ahern^{1,3,5}, Anna Kuchel^{1,3,5}, Melissa Eastgate^{3,5}, Sally Pearson¹, Domenico Mallardo⁶, Paolo A. Ascierto⁶, Daniela Massi⁷, Barbara Merelli⁸, Mario Mandala⁸, James S. Wilmott⁹, Alexander M. Menzies⁹, Charles Leduc¹⁰ John Stagg^{1,11}, Bertrand Routy¹¹, Georgina V. Long⁹, Richard A. Scolyer^{9,12, 13}, Tobias Bald¹⁴, Nicola Waddell⁴, William C. Dougall¹, Michele W. L. Teng^{2,3}, Mark J. Smyth^{1,3*}

1. Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, QLD, Australia.

2. Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, QLD, Australia.

3. School of Medicine, University of Queensland, QLD, Australia.

4. Medical Genomics, QIMR Berghofer Medical Research Institute, QLD, Australia.

5. Department of Medical Oncology, Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia.

6. Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Instituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

7. Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

8. Department of Oncology and Haematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

9. Melanoma Institute Australia, The University of Sydney, NSW, Australia

10. Department of Pathology, University of Montreal Health Center

11. Research Centre, University of Montreal Hospital, Montréal, Canada.

12. Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.

13. Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW 2050, Australia.

14. Oncology and Cellular Immunology, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

These authors contributed equally to this work.

*Corresponding author: <u>Mark.Smyth@qimrberghofer.edu.au</u>

Professor Mark J. Smyth, QIMR Berghofer Medical Research Institute, 300 Herston

Road, Herston, 4006, Qld, Australia. PH: 61-7-3845-3957

Running title: CD155 and resistance to immune checkpoint blockade

Conflict of Interest

Disclosures: MJS has research agreements with Bristol Myers Squibb, Aduro Biotech and Tizona Pharmaceuticals and is on the scientific advisory board of Tizona Therapeutics and Compass Therapeutics. MWLT has received speaker's honorarium from Roche, MSD, and BMS. WCD has received research funding from Bristol Myers Squibb and is a consultant for Omeros Corporation and Cascadia Drug Development Group. T.B. has research agreements with Bristol Myers Squibb and Ena Therapeutics and is member of the Scientific Advisory Board of Oncomyx. EA honorarium from Amgen Australia, has speaker's Conference/meeting travel/accommodation expenses or sponsorship from MSD, BMS, Roche, Amgen. GVL is consultant advisor to Aduro, Amgen, BMS, Merck MSD, Novartis, Roche. PAA is consultant advisor to BMS, Roche-Genentech, MSD, Array, Novartis, Merck Pierre Fabre. Incyte, Genmab, Newlink Genetics, Serono. Medimmune. AstraZeneca. Syndax, Sun Pharma, Sanofi, Idera. Ultimovacs. Sandoz. Immunocore, 4SC, Research Funds from BMS, Roche-Genentech, Array, Travel support from MSD. RAS has served on advisory boards for Merck Sharp Dohme, Glaxo Smith Kline Australia, Bristol Myers Squibb, Novartis Pharmaceuticals Australia, Myriad, Amgen, and NeraCare, unrelated to the content of this work. All other authors declare that they have no conflict of interest.

Abstract

Purpose: Resistance to anti-PD1 based immune checkpoint blockade (ICB) remains a problem for the treatment of metastatic melanoma. Tumor cells as well as host myeloid cells can express the immune checkpoint ligand CD155 to regulate immune cell function. However, the effect of tumor CD155 on the immune context of human melanoma has not been well described. This observational study characterizes tumor CD155 ligand expression by metastatic melanoma tumors and correlates results with differences in immune cell features and response to ICB.

Design: Pre-treatment tumor specimens, from 155 metastatic melanoma patients treated with ICB and from 50 patients treated with BRAF/MEK-directed-targeted therapy, were assessed for CD155 expression by immunohistochemistry. Intratumor T cell features were analysed using multiplex-immunohistofluorescence for CD8, PD1 and SOX10. Correlations were made between CD155 tumor level and bulk tumor RNA-seq results, as well as clinical RECIST response and progression-free survival.

Results: High pretreatment CD155 tumor levels correlated with high parenchymal PD1⁺CD8⁺/CD8⁺ T cell ratios (PD1^{tR}) and poor response to anti-PD1 therapy. In PD-L1 negative tumors, high CD155 tumor expression was associated with patients who had poor response to combination anti-PD1/CTLA4 therapy.

Conclusion: Our findings are the first to suggest that tumor CD155 supports an increase in the fraction of PD1⁺CD8⁺ T cells in anti-PD1 refractory melanoma tumors

and, further, that targeting the CD155 pathway might improve response to anti-PD1 therapy for metastatic melanoma patients.

Translational relevance

This is the first study to demonstrate that high tumor CD155 expression affects response to anti-PD1 therapy in metastatic melanoma patients. CD155 promotes anti-PD1 resistance and increased PD1 expression on CD8⁺ T cells within melanoma tumor parenchyma.

Key words

CD155, immunotherapy, metastatic melanoma, immunotherapy resistance, PD1, CTLA4, CD96, TIGIT.

Introduction

Tumor cells can upregulate immune checkpoint ligands to suppress T cell function (1-3). Immune checkpoint blockade (ICB) can control tumor growth and sometimes leads to regression of metastatic disease. ICB therapy targeting the inhibitory receptor PD1 (anti-PD1) is the most effective single agent ICB treatment to date, while combination ICB targeting both PD1 and CTLA4 (anti-PD1/CTLA4) further increases response rates, however with increased immune-related toxicity (4-7). In contrast to BRAF-directed targeted therapy (BRAFi; BRAF or combination BRAF/MEK inhibition), ICB therapies can induce durable long-term anti-tumor immune responses. These therapies have materially changed prognosis for patients with metastatic melanoma. Nevertheless, primary resistance to ICB is common, and one-third of ICB-treated melanoma patients who have an initial response will subsequently progress (8). Further, existing biomarkers to predict response to ICB therapy are controversial and limited by an incomplete understanding of the pretreatment immunological features of the tumor microenvironment. Resistance to ICB can involve a number of factors or causes, including the upregulation of other inhibitory checkpoints (9,10). As such, significant efforts are underway to understand which factors in the tumor microenvironment modify sensitivity to current ICB therapies in order to define alternative or ancillary immune checkpoint targets that improve outcomes and minimize toxicity.

A novel ICB target is the adhesion molecule CD155, which additionally functions as an immune checkpoint ligand expressed by tumor cells and tumor-associated myeloid cells (11). CD155 modifies lymphocyte function through multiple cognate

immune receptors; TIGIT, CD96, and CD226 (DNAM-1), expressed by T cells and NK cells. CD155 is upregulated on tumor cells across multiple solid cancer types, including melanoma, and has been shown to be advantageous to tumor growth and tumor survival (12). Recently, using mouse tumor models in which CD155 was knocked-out (CD155^{KO}), we demonstrated that loss of tumor CD155 increased sensitivity to combination anti-PD1/CTLA4 treatment in vivo (11), suggesting that cotargeting CD155 may complement current ICB therapies. It is unclear in humans to what extent tumor CD155 impacts the immune infiltrate contexture or if expression of CD155 in human cancers affects sensitivity to immunotherapies. In this study, we characterize CD155 expression in human metastatic melanoma and provide evidence for a significant correlation between high CD155 and decreased sensitivity to ICB therapies. In PD-L1 negative tumors, high tumor CD155 identified those patients who did not respond to combination anti-PD1/anti-CTLA4 therapy. We demonstrated that tumor CD155 correlated with an increase in the ratio of PD1⁺CD8⁺ T cells infiltrating melanoma tumor parenchyma, but not among T cells localized within the tumor stroma. Further, a high intratumor PD1⁺CD8⁺/CD8⁺ T cell ratio (PD1^{tR}) was a predictor of poor response to PD1-based ICB therapy.

Results

High tumor CD155 limits response of metastatic melanoma patients to α PD1-combitherapy

Following from our preclinical studies using mouse tumor models (11), we wanted to understand the impact of CD155 in human cancer. We characterized tumor CD155 protein levels using immunohistochemistry (IHC) in pretreatment surgical specimens from metastatic melanoma patients who were treated with ICB (either anti-PD1 alone $[\alpha PD1-monotherapy]$ or in combination with anti-CTLA4 $[\alpha PD1-combitherapy]$ or BRAFi therapy (Figure 1A). In pretreatment tumor specimens (n = 155 ICB treated; n= 50 BRAFi therapy), intra-tumor membrane staining for CD155 was highly constitutive/homogeneous. This is in contrast to the high intra-tumor heterogeneity and low-level expression observed for PDL1 in metastatic melanomas (13). However, considerable variation in the level of intra-patient CD155 membrane staining intensity was observed. Briefly, 5% (10/205) of melanoma pretreatment specimens were negative for CD155 (score 0+), 22% (45/205) were classified as membrane score 1+, 37% (75/205) were score 2+, and 37% (75/205) were score 3+ (Table 1). CD155 score 3+ tumors were characterized by strong circumferential membrane staining. Overall, this indicates that expression of CD155 by tumor cells is common in metastatic melanoma (>95%) but that significant inter-patient variability exists at the level of CD155 membrane expression.

To appreciate if tumor CD155 might influence response to ICB, we compared RECIST response categories (14) with pretreatment CD155 H-scores from patients treated with either α PD1-combitherapy or α PD1-monotherapy. We found that α PD1-combitherapy patients whose pretreatment tumors were CD155 score 3+ (CD155^{high})

demonstrated higher rates of stable disease (SD) or progressive disease (PD) as their best ICB response, and lower rates of complete response (CR) or partial response (PR), compared to patients who had CD155 low tumors (score 0+, 1+, 2+ [CD155^{low}]; P = 0.042, Fisher Exact Probability Test [FEPT; Figure 1B). Further, a significant association between disease progression within 6 months of ICB commencement and high CD155 tumor levels in α PD1-combitherapy treated melanoma patients was observed (P = 0.007, FEPT; Figure 1C). Interestingly, in melanoma patients treated with BRAFi therapy, CD155^{high} tumors had a better RECIST response profile (P = 0.002, FEPT; Figure 1B), but not better or worse PFS (Figure 1C).

Associations between CD155 and therapy response were further evaluated using progression-free survival (PFS) and Kaplan-Meier-Cox proportional hazard modeling. For melanoma patients treated with α PD1-combitherapy, median PFS was shorter in those patients with CD155^{high} tumors compared with CD155^{low} tumors (HR = 2.886 [1.11 - 7.504]; *P* = 0.007; Figure 1D). For α PD1-monotherapy-treated patients, a similar trend in PFS was observed but it did not reach statistical significance (Figure 1D). For patients treated with BRAFi therapy, no difference in PFS by CD155 tumor expression levels was observed (Figure 1D) even though CD155^{high} tumors responded better to BRAFi therapy by RECIST criteria (Figure 1B). A comparison of PFS between α PD1-monotherapy and α PD1-combitherapy (HR = 2.0 [1.1 - 3.8]; *P* = 0.032), but no significant benefit was seen in CD155^{high} patients by the addition of anti-CTLA4 therapy (HR = 1.0 [0.5 - 2.1]; *P* = 0.933; Figure S1A).

CD155^{high}/PD-L1^{negative} melanomas respond poorly to anti-PD1 therapy and show decreased expression of critical genes involved in T cell function.

We next compared tumor CD155 with immunotherapy outcome for PDL1 negative and PD-L1 positive melanomas. Patients whose tumors were PDL1 negative and CD155^{high} had poor RECIST response (no PR or CR in this group; Figure 2A), regardless of whether they received α PD1-combitherapy (P = 0.0009) or α PD1monotherapy (P = 0.05). Patients treated with α PD1-combitherapy whose tumors were PD-L1 negative and CD155^{high} also had worse 6-month PFS rates (P = 0.05; Figure 2B), and shorter median PFS (HR = 6.12 [1.3 – 29.8]; P < 0.0001; Figure 2C). In contrast, patients with PD-L1 negative tumors whose CD155 expression was low had better PFS outcome, similar to those patients whose tumors were PD-L1 positive.

We next wanted to understand how the level of CD155 protein expressed by tumor cells affected the immune cell contexture in human tumors. Gene expression data generated from pretreatment tumor specimens from 41 metastatic melanoma patients were analyzed and compared to CD155 scores from surgically matched archival-FFPE tumor specimens. Using principal component analysis, no association between PC1 or PC2 and CD155 IHC score was determined, suggesting that CD155 was not associated with features underlying the basic biology of these tumors (Figure S1B). CD155 score by IHC correlated significantly with *PVR* (*CD155*) gene expression (r = 0.604; *P* < 0.001; Figure S1C). Next, we determined differentially expressed (DE) genes between CD155 score 1+ versus score 3+ tumors to represent low and high levels of CD155 protein expression (n = 867 genes, p-value <

0.01; Table S1). Reactome pathway analyses were used to identify significantly enriched biological processes. Pathways significantly down-regulated in CD155 score 3+ tumors included interferon-gamma signaling among other T cell related pathways (Figure 2D, Figure S1D), which suggested an association between CD155 and reduced CD8⁺ T cell function. Genes in the interferon signaling pathway DE between CD155 score 1+ vs 3+ are shown in the heatmap clustered by CD155 score and PD-L1 status (Figure 2E). Out of 52 DE genes, 51 were downregulated in CD155^{high} tumors. Among score 3+ tumors, there were outlier patients who had a PFS response > 6 months and these tumors were often PD-L1 positive and showed higher expression of IFN-related genes. Together, these data suggest that CD155 plays a critical role in promoting tumor immune suppression in the context of anti-PD1 therapy but that this suppression might be overcome by a robust pre-existing pretreatment immune response.

Tumor CD155 correlates with increased PD1 expression on tumor-infiltrating CD8⁺ T cells

RNA-seq analysis of pretreatment melanoma specimens suggested that tumor CD155 might influence the phenotype and function of tumor-infiltrating CD8⁺ T cells. Here, we used multiplex-immunohistofluorescence (multiplex-IF) to examine the expression of the key inhibitory receptor PD1 on CD8⁺ T cells (Figure 3A). Melanoma tissue arrays or whole slide tissue sections from archival specimens were used and multiplex-IF data were matched to CD155 H-scores. Samples were enriched for high lymphocyte content selected by a pathologist using morphologically stained (H&E) slides. Tumor parenchyma (SOX10⁺) and stromal regions (SOX10⁻) were separately analyzed (Figure 3B). Parenchymal CD8⁺ T cell counts did not

10

correlate with tumor CD155 score indicating that T cell infiltration is independent of tumor CD155 score (Figure 3C). In contrast, the number of parenchymal PD1⁺CD8⁺ T cells significantly correlated with increasing CD155 score (r = 0.248; P = 0.015; Figure 3C). Notably, the ratio of parenchymal PD1⁺CD8⁺ T cells to total CD8⁺ T cells (PD1^{+R}) significantly correlated with tumor CD155 score (r = 0.359; P = 0.0001; Figure 3C). These correlations were validated in an independent cohort of pretreatment melanoma specimens from patients who received targeted therapy only (Figure 3D). Interestingly, no correlation was found for the same ratio calculated for stromal-localized PD1⁺CD8⁺ T cells (data not shown). In summary, our data support the notion that tumor CD155 protein expression is associated with increased PD1 expression on tumor-infiltrating CD8⁺ T cells specifically within a PD1^{high} CD8⁺ T cell phenotype, but does not affect the recruitment of T cells into the melanoma parenchyma.

Increased PD1^{tR} is associated with progressive disease and early disease progression

We evaluated the impact of high PD1^{tR} on RECIST categories and PFS outcome. Compared to CD155 score, a high PD1^{tR} was more significantly associated with good RECIST categories and with higher rates of PD and SD in α PD1-combitherapy and α PD1-monotherapy treated melanoma patients (*P* = 0.001 and 0.007 respectively, FEPT; Figure 4A). A significant association between disease progression within 6 months of ICB commencement and high PD1^{tR} in α PD1combitherapy and α PD1-monotherapy treated melanoma patients was observed (*P* = 0.008 and 0.007 respectively, FEPT; Figure 4A). Shorter PFS correlated with high PD1^{tR} in α PD1-combitherapy treated melanoma patients (HR = 7.301 [1.808 –

11

29.49]; P = 0.0032) and in α PD1-monotherapy treated patients (HR = 1.905 [0.7571 – 4.793]; P = 0.094; Figure 4C). We next compared the predictive value of PD1^{tR} with therapy-specific outcome. As expected, α PD1-combitherapy resulted in better PFS for melanoma patients with low PD1^{tR}, compared to α PD1-monotherapy (HR = 5.658 [2.431 - 13.17]; P = 0.007; Figure S1A). However, for melanoma patients with high PD1^{tR}, α PD1-combination therapy did not lead to improved PFS over that seen for patients treated with α PD1-monotherapy (HR = 1.582 [0.6108– 4.1]; P = 0.345; Figure S1A). We additionally wanted to understand if the effect of PD1^{tR} on outcome was specific to immunotherapy treated patients. In *BRAF*-mutated melanoma patients who did not receive anti-PD1 therapy, but received BRAFi therapy, there was no association between RECIST response or PFS outcome with PD1^{tR} (Figure 4C).

Discussion

Development of alternative checkpoint therapies to compliment or substitute anti-PD1 and anti-CTLA4 are the subject of intensive academic and industrial pharmaceutical studies. In the current study we found that in metastatic melanoma, pretreatment CD155 tumor levels affected response to aPD1-combination therapy suggesting that targeting the CD155 pathway might be beneficial in anti-PD1 refractory melanoma patients. A possible mechanism underpinning this observation is tumor CD155 signaling through the immune checkpoint receptors CD96 and TIGIT to promote CD8⁺ T cell inhibition. Elevated CD155 tumor expression was found to correlate with an increase in the ratio of PD1⁺CD8⁺ T cells within the tumor parenchyma (PD1^{tR}), and this increase was associated with progressive disease and early time to progression among aPD1-combination treated melanoma patients. The detrimental effect of high CD155 expression was evident but was not statistically significant in aPD1-monotherapy treated patients. One explanation for this might be the greater effectiveness of aPD1-combination therapy (15), resulting in more impressive RECIST response and survival outcomes for patients with favorable tumor CD155 expression. Further, CD155 suppression of therapeutic response was specific to ICB-treated patients as it was not observed in melanoma patients treated with BRAFi therapy, indicating that tumor CD155 specifically limits sensitivity to ICB therapy in metastatic melanoma. Indeed, in BRAFi-treated patients a high tumor CD155 predicted better RECIST response albeit with no difference in PFS compared to patients whose tumors were CD155 low. Given these data, we hypothesize that co-targeting the CD155 pathway (CD96/TIGIT co-blockade) in combination with anti-PD1 therapy might increase response rates in anti-PD1 refractory patients.

Analysis of the spatial distribution of lymphocyte subsets in tumors can be predictive and reveal aspects of tumor biology not apparent in gross T cell estimations typically achieved in flow cytometry data (16-18). We found a positive correlation between CD155 tumor levels and PD1^{tR} when lymphocytes were counted within the tumor parenchyma, but not for lymphocytes counted within the tumor stroma. This suggests that PD1^{tR} might partially be driven by the interaction of the CD155 ligand on tumor cells with its cognate T cell receptors (TIGIT and CD96). Further this parenchymal interaction of tumor CD155 and T cells could be affecting sensitivity to anti-PD1 therapy (11). Better PFS outcome was observed in CD155^{high} tumors which had a favorable pretreatment PD-L1 status and IFN gene signatures, reflecting an active pretreatment anti-tumor immune response (19-22). However, no apparent statistical benefit from combination therapy coupled with the inferior survival outcomes in melanoma patients with CD155^{high} or high PD1^{tR} tumors suggests that additional or alternative treatment approaches are required for those patients, possibly including blockade of CD155 interactions with TIGIT and CD96. The immunosuppressive effect of CD155 on response to anti-PD1 therapy was most apparent in PD-L1 negative tumors that scored 3+ for CD155, regardless of ICB therapy type, and this group of patients showed no complete or partial RECIST responses.

Interestingly, CD155 negative tumors consistently demonstrated excellent outcome to ICB therapy, however, RNA-seq of CD155 negative melanoma tumors indicated a diminished IFN gene signature and were often PD-L1 negative. This suggests that tumors of this type do not contain a pre-treatment immune response and this is particularly interesting given that PD-L1 negative tumors with limited IFN gene signatures are generally thought to respond poorly to immunotherapy (19-22). However, CD155 has an intrinsic role in mediating tumor cell growth and invasion and these tumors may represent a less aggressive melanoma tumor type (11). Nevertheless, given the positive response of CD155 negative tumors to ICB, the absence of an existing intra-tumor immune response before treatment must not preclude the development of one on treatment, at least not in CD155 negative tumors is unknown and this may be an intrinsically positive prognostic factor independent of ICB treatment. In any case CD155 negative melanomas are rare (<5%) and the biology of CD155 negative tumors deserves greater scrutiny.

We have previously shown in mice that expression of CD155 in the tumor microenvironment limits the efficacy of tumor growth control by T and NK cells (11,23,24). Recently, it has been shown that PD1^{hi}CD8⁺ T cells in chronic infection and cancer are dysfunctional and in fact epigenetically repressed and terminally differentiated, as such, this population is insensitive to anti-PD1 therapy (25,26). Given that multiplex-IF is less sensitive than conventional flow cytometry, it may be reasonable to assume that PD1⁺CD8⁺ T cells as detected by multiplex-IF in patient samples are those expressing the highest levels of PD1 (PD1⁺CD8⁺ = PD1^{hi}CD8⁺) and therefore likely to have a dysfunctional phenotype. While we have not demonstrated that the PD1⁺CD8⁺ T cell population observed by multiplex IHC in pretreatment human melanoma specimens was dysfunctional *per se*, the combination of our observations made by IHC and bulk tumor RNA-seq supports a model in which tumor cell CD155 expression correlates with high PD1^{tR} levels

15

thought to be associated with a dysfunctional CD8⁺ T cell phenotype. Importantly, varied mechanisms of resistance to anti-PD1 therapy can affect response rates (9,27-30), nevertheless, CD155 is commonly expressed in metastatic melanoma lesions (>95%) indicating the CD155 pathway is an attractive immunotherapy co-target in anti-PD1 ICB therapy.

CD8⁺ T cells infiltrating human melanoma also express TIGIT and CD96 in addition to PD1 (24,31,32). Therefore, it may be reasonable to propose that the inhibitory signaling mediated not only through PD1, but also CD96 and TIGIT, drives T cell dysfunction. Indeed, co-blockade of PD1 and CD96 in established CT26 colon adenocarcinomas increased IFNγ production above that observed for anti-PD1 blockade, suggesting that these cell populations may be amenable to functional reinvigoration (23). Further, therapeutic blockade of TIGIT and CD96 had superior activity in controlling primary tumor growth compared to α PD1-monotherapy in B16F10 melanoma tumor models (23). In mouse tumor models using CD155deficient mice, it was previously shown that both tumor and host CD155 were critical for tumor growth, so therapeutic targeting of TIGIT and CD96 must take this into consideration (11). The contribution of CD155-dependent signaling could potentially be assessed in early-phase clinical trials of anti-TIGIT as monotherapy or in combination with anti-PD1 (NCT02964013), and in other future randomized controlled trials targeting members of this pathway.

In summary, we have shown that high expression of CD155 in metastatic melanoma correlates with an increase in the intratumor ratio of PD1⁺CD8⁺/CD8⁺ T cells, abbreviated here as PD1^{tR}, and reduced sensitivity to α PD1-combitherapy. It is likely

that PD1⁺CD8⁺ T cells detected by multiplex-IF are of a PD1^{hi} phenotype and thus dysfunctional and resistant to PD1-based ICB reinvigoration. Further CD155 combined with PD-L1 might be a useful predictor of a group of patients who do not respond to anti-PD1 ICB. Our findings give impetus for validation in a prospective cohort the utility of CD155 plus PD-L1 as a predictive biomarker, and for clinical trials to assess therapies blocking CD96/TIGIT or CD155 in combination with anti-PD1 therapy.

Methods

Patients and specimens

The study was approved by the QIMR Berghofer Human Research Ethics Committee (HREC). Research involving human subjects was also approved by HRECs at each clinical site and was conducted according to the Declaration of Helsinki. Where prospective biospecimen collection was undertaken, informed consent was granted by study participants. For retrospective annotated specimens a waiver of consent was gained by the site HREC. Retrospective archival-FFPE tissue specimens were obtained for patients with radiologically confirmed stage IV melanoma (AJCC) from four institutional sites; Melanoma Institute Australia [MIA], Royal Brisbane Women's Hospital [RBWH], Istituto Nazionale Tumori - IRCCS [INT-IRCCS], and Papa Giovanna XXIII Hospital [PG-XXIII]. Presence of tumor cells was monitored by H&E staining. Patient demographics, primary tumor characteristics and therapy details are listed in Table-1. Fresh tumor specimens for RNA-seq analysis were collected through the MIA tumor biobank. REMARK guidelines (33) were followed where data were available from the contributing institute.

Immunohistochemistry

Archival-FFPE tumors were sectioned at 3 µm on superfrost+ slides. Slides were dehydrated at 65°C for 20 min, deparaffinized in xylene and rehydrated in graded ethanol. Antigen retrieval was performed in EDTA buffer (pH 9) in a Decloaking Chamber (Biocare Medical) at 100°C for 20 min. IHC was performed on an Autostainer-Plus (DAKO). Primary antibodies against CD155 (D3G7H; CST#13544) or PDL1 (E1L3N; CST#13684) were incubated for 45 minutes at room temperature using a 1:100 dilution for CD155 or 1:150 for PDL1. Staining was visualized using a

Rabbit-HRP-polymer detection system (Biocare; M3R531) and DAB Chromogen Kit (Biocare; BDB2004) and counterstained with diluted hematoxylin. IHC was evaluated for two representative high-power fields of view noting the percentage of membrane positive tumor cells and the maximum intensity of immunohistochemical signal (0+ to 3+). CD155 score was assigned using the blinded H-score method and categorized as follows; score 0+ (negative), score 1+ (0 - 99), score 2+ (100 - 199), or score 3+ (200 - 300). PDL1 score was assigned as the combined percentage of PDL1 positive tumor and inflammatory cells per representative whole specimen slide.

Multiplex immunohistofluorescence

Archival-FFPE tissue specimens were sectioned at 3 µm onto Superfrost+ slides. Slides were then deparaffinized, rehydrated, and washed in tris-buffered saline with 0.01% Tween-20 (TBS-T). Antigen retrieval was performed in modified citrate buffer pH 6.1 (Agilent; S169984-2) at 100°C for 20 minutes. All multiplex steps were performed using an Autostainer Plus (Dako, Agilent Technologies) with two TBS-T washes between each step. Tissue sections were blocked with 3% hydrogen peroxide in TBS-T for 5 min and background sniper for 10 min (Biocare Medical). Sequential staining was performed using the Opal method (PerkinElmer) with antibody stripping steps performed in Tris/EDTA buffer (Agilent; S236784-2) at 100°C for 20min. Primary antibodies incubated for 30 minutes, followed by two-step polymer-HRP detection (Biocare; Mach3) and then labeled with TSA-based fluorophores (PerkinElmer; Opal Reagent Pack). following The primary antibodies/clones were used sequentially in the order listed; PD1/NAT105 (1:500;Opal520), CD8/144b (1:7500; Opal570), and SOX10/BC34 (1:600; Opal690). Slides were counterstained with DAPI and cover-slipped (DAKO; S3023).

Multiplex-IF Image acquisition and analysis

Images were obtained using the Vectra 3.0 slide scanner (PerkinElmer) under the appropriate fluorescent filters. A fluorescent whole slide scan at 4x was produced and visualized in Phenochart (v1.0.4), followed by multispectral image acquisition of each TMA core or selected high power regions at 20x. Multispectral images were spectrally unmixed followed by tissue and cell segmentation using InForm analysis software (v2.2.1). Nuclear expression of SOX10 by tumor cells was used to segment melanoma tumor parenchyma and stroma tissue regions. Merged data files from InForm were pre-processed and fluorescence thresholds were set using Spotfire image-mapping tools for each marker (PD1⁺, CD8⁺, and SOX10⁺; Tibco Spotfire Analyst, v7.6.1) followed by segmented cell counting using Spotfire and tabulation in Microsoft Excel.

RNA-seq preparation, data processing, and differential expression analysis

RNA-seq was performed on pretreatment tumor specimens from 41 metastatic melanoma patients treated with immunotherapy at Melanoma Institute Australia. Briefly, total RNA was isolated from fresh frozen tissue sections using the AllPrepDNA/RNA/miRNA Universal kit (Qiagen) according to the manufacturer's instructions (34,35). RNA quantity was assessed on Qubit, and RNA integrity was assessed using the RNA 6000 Nano kit and run on the Agilent 2100 Bioanalyzer (Agilent Technologies). cDNA synthesis and library construction were performed using the TruSeq RNA Library Prep Kit (Illumina) and paired-end 100bp sequencing, with each sample yielding 40-50 million read. Sequencing was performed on the Illumina Hiseq 2500 platforms at the Australian Genome Research Facility in

Melbourne. Fastq data were downloaded and sequence reads were trimmed for adapter sequences using Cutadapt (version 1.9)(36) and aligned using STAR (version 2.5.2A) to the GRCh37 human reference genome assembly using the gene, transcript, and exon features model of Ensembl (release 70). Quality control metrics were computed using RNA-SeQC (version 1.1.8) and transcript abundances were quantified using RSEM (version 1.2.30). Further analysis of the RNA-seg data was carried out in R (version 3.5.1). Protein-coding genes with < 3 counts per million in fewer than 5 samples were removed from down-stream analyses. Trimmed mean of M-values (TMM) normalization and differential gene expression analysis were performed using the edgeR package (37). The 'prcomp' function in R was used to perform principal component analysis on gene-wise centered and scaled values of TMM normalized expression data. То perform pathway analysis, the `clusterProfiler::bitr` function (38) was used to convert gene IDs from Ensembl to Entrez, then consequently passed to the `ReactomePA::enrichPathway` function (39), before plotting the results with the `clusterProfiler::dotplot` function (38). Heatmaps were produced using `ComplexHeatmap` R package (40,41) using genewise centered, scaled, log2 values of TMM normalized expression data, and "Pearson" distance with "ward.D" criteria to cluster the rows. Cytolytic activity was calculated as the geometric mean of GZMA and PRF1 (as expressed in TPM) as per (40). RNA-seq data analyzed in this study have been published (42) and deposited in the European Genome-phenome Archive (EGA) under dataset accession EGAD00001005501 and study accession EGAS00001001552.

Outcome analysis

Univariate survival analysis was carried out by fitting Cox proportional hazard models to dichotomize patient groups according to respective variables and the survival variable. Cut-off points for the dichotomized variable were calculated as the arithmetic mean of the two successive values which gave the most significant log-rank split using cut-off finder version 2.0(43). Hazard ratios (HRs) including 95% confidence intervals are calculated and log-rank *P* values given. PFS was defined as time from commencement of therapy to documented disease progression (PFS). Response to ICB was assessed by site investigators using timepoint RECIST version 1.1 (i.e. best response in time-point fashion).

Statistical methods and data availability

Correlations between categorical clinical variables and experimental variables (CD155, PD1^{tR}) were calculated using a two-tailed Fisher Exact Probability Test (FEPT). Correlations of CD155 immunohistochemistry with immune cell counts by multiplex-IF were performed using Pearson r method. Statistical analyses listed in figure legends were performed using PRISM. All data for multiplex-IF and chromogenic IHC supporting the findings of this study are available from the corresponding author upon reasonable request. RNA-seq data have been deposited in the European Genome-Phenome Archive (accession number: EGAD00001005501).

Author Contributions: Conceptualization, M.J.S., J.M., A.L., W. C. D.; Methodology, J.M., A.L., R.L.J.; Investigation, A.L., J.M., E. McD., R.L.J.; Formal Analysis, J.M.; A.L.; J.S.O'D., R.L.J.; Writing – Original Draft, J.M., J.S.O'D.; Writing – Review & Editing, A.L., M.J.S., M.W.L.T., E.A., A.K., T.B., J.S.W., G.V.L., R.A.S., W.C.D.,; Resources, M.J.S., M.W.L.T., A.K., M.E., D.M., P.A.A., D.M., B.M., M.M., J.S.W., A.M.M., C. L., J.S., B.R., G.V.L., R.A.S.; Data Curation, E.A., A.K.; Supervision, M.J.S., M.W.L.T., N.W.; Funding Acquisition, M.J.S., M.W.L.T..

Acknowledgements

We thank the patients who participated in this study; clinical faculty and personnel, including; Bianca Nowlan for technical assistance; Gunter Hartel for statistical support, the histology and microscopy department at QIMR Berghofer, staff and clinicians at Melanoma Institute Australia; Helen Rizos and Richard Kefford for providing tumor specimens. The authors also thank Robert Johnston, Bristol Myers Squibb, for very helpful discussion.

Financial support: A. L., J. M. and W. C. D. and some of the work were supported by a scientific research agreement from Bristol Myers Squibb and a project grant from the Australian Skin and Skin Cancer Research Centre. S. P. was supported by philanthropic funding from Terry Jackman. T. B. was supported by a National Health and Medical Research Council (NH&MRC) Early Career Research Fellowship (1138757). M. W. L. T. was supported by a NH&MRC Career Development Fellowship (1159655) and Project Grant (1120887). M. J. S. was supported by a NH&MRC Senior Principal Research Fellowship (1078671), a NH&MRC Program Grant (1132519) and a CCQ Project Grant (1157048). For R. A. S. some of this work was supported by a NHMRC Program Grant (G. V. L & R. A. S.) and the NHMRC Fellowship program (J. S. W., G. V. L. & R. A. S.). Funding support from Melanoma Institute Australia (MIA) and The Ainsworth Foundation is also gratefully acknowledged. The authors also thank colleagues at Royal Prince Alfred Hospital and MIA for assistance.

References

- 1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity **2013**;39(1):1-10 doi 10.1016/j.immuni.2013.07.012.
- O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology 2019;16(3):151-67 doi 10.1038/s41571-018-0142-8.
- 3. Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell **2018**;33(4):547-62 doi 10.1016/j.ccell.2018.03.012.
- Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018;378(22):2093-104 doi 10.1056/NEJMoa1801946.
- 5. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, *et al.* Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med **2015**;373(1):23-34 doi 10.1056/NEJMoa1504030.
- Long GV, Larkin J, Ascierto PA, Hodi FS, Rutkowski P, Sileni V, et al. PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis. Annals of Oncology 2016;27(suppl_6) doi 10.1093/annonc/mdw379.07.
- 7. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov **2018**;8(9):1069-86 doi 10.1158/2159-8290.CD-18-0367.
- Schachter J, Ribas A, Long GV, Arance A, Grob J-J, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;390(10105):1853-62 doi 10.1016/S0140-6736(17)31601-X.
- 9. Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, *et al.* Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell **2019**;35(2):238-55.e6 doi 10.1016/j.ccell.2019.01.003.
- Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting **2019**;39:147-64 doi 10.1200/edbk_240837.
- 11. Li X-Y, Das I, Lepletier A, Addala V, Bald T, Stannard K, *et al.* CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest **2018**;128(6):2613-25 doi 10.1172/JCI98769.
- 12. Bevelacqua V, Bevelacqua Y, Candido S, Skarmoutsou E, Amoroso A, Guarneri C, *et al.* Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget **2012**;3(8):882-92 doi 10.18632/oncotarget.594.
- Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment cell & melanoma research 2015;28(3):245-53 doi 10.1111/pcmr.12340.

- 14. Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, *et al.* RECIST 1.1-Update and clarification: From the RECIST committee. European journal of cancer (Oxford, England : 1990) **2016**;62:132-7 doi 10.1016/j.ejca.2016.03.081.
- 15. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine **2017**;377(14):1345-56 doi 10.1056/NEJMoa1709684.
- 16. Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, *et al.* Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck **2016**;38(7):1074-84 doi 10.1002/hed.24406.
- 17. Oguejiofor K, Hall J, Slater C, Betts G, Hall G, Slevin N, *et al.* Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. Br J Cancer **2015**;113(6):886-93 doi 10.1038/bjc.2015.277.
- 18. Shimizu S, Hiratsuka H, Koike K, Tsuchihashi K, Sonoda T, Ogi K, *et al.* Tumor-infiltrating CD8 T-cell density is an independent prognostic marker for oral squamous cell carcinoma. Cancer Med **2019**;8(1):80-93 doi 10.1002/cam4.1889.
- 19. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, *et al.* IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest **2017**;127(8):2930-40 doi 10.1172/JCI91190.
- 20. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell **2017**;168(3):542 doi 10.1016/j.cell.2017.01.010.
- 21. Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, *et al.* Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer discovery **2014**;4(6):674-87 doi 10.1158/2159-8290.Cd-13-0458.
- 22. Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Advances in experimental medicine and biology **2017**;1036:19-31 doi 10.1007/978-3-319-67577-0_2.
- 23. Blake SJ, Stannard K, Liu J, Allen S, Yong MCR, Mittal D, *et al.* Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discov **2016**;6(4):446-59 doi 10.1158/2159-8290.CD-15-0944.
- 24. Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, et al. CD96 Is an Immune Checkpoint That Regulates CD8 T-cell Antitumor Function. Cancer Immunology Research **2019**;97(2):152-64 doi 10.1158/2326-6066.cir-18-0637.
- 25. Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, *et al.* A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer research **2015**;75(18):3800-11 doi 10.1158/0008-5472.Can-15-1082.
- 26. Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, *et al.* The epigenetic landscape of T cell exhaustion. Science **2016**;354(6316):1165-9 doi 10.1126/science.aae0491.

- 27. Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nature reviews Clinical oncology **2016**;13(3):143-58 doi 10.1038/nrclinonc.2015.209.
- 28. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature **2015**;523(7559):231-5 doi 10.1038/nature14404.
- 29. Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, et al. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Science translational medicine **2018**;10(436) doi 10.1126/scitranslmed.aan3311.
- 30. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, *et al.* Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell **2016**;167(2):397-404.e9 doi 10.1016/j.cell.2016.08.069.
- 31. Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, *et al.* TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. The Journal of clinical investigation **2015**;125(5):2046-58 doi 10.1172/jci80445.
- 32. Lepletier A, Lutzky VP, Mittal D, Stannard K, Watkins TS, Ratnatunga CN, *et al.* The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells. Immunol Cell Biol **2019**;97(2):152-64 doi 10.1111/imcb.12205.
- 33. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). British journal of cancer **2005**;93(4):387-91 doi 10.1038/sj.bjc.6602678.
- 34. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, *et al.* Whole-genome landscapes of major melanoma subtypes. Nature **2017**;545(7653):175-80 doi 10.1038/nature22071.
- 35. Wilmott JS, Hayward NK, Mann GJ, Scolyer RA. Advantages of wholegenome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project. Melanoma management **2017**;4(3):147-9 doi 10.2217/mmt-2017-0008.
- 36. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011 **2011**;17(1):3 doi 10.14806/ej.17.1.200.
- 37. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (Oxford, England) **2010**;26(1):139-40 doi 10.1093/bioinformatics/btp616.
- 38. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics : a journal of integrative biology **2012**;16(5):284-7 doi 10.1089/omi.2011.0118.
- 39. Yu G, He QY. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Molecular bioSystems **2016**;12(2):477-9 doi 10.1039/c5mb00663e.
- 40. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell **2015**;160(1-2):48-61 doi 10.1016/j.cell.2014.12.033.
- 41. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics (Oxford, England) **2016**;32(18):2847-9 doi 10.1093/bioinformatics/btw313.

- 42. Lee J SE, Shklovskaya E, Lim SY, Carlino M. Menzies A, Stewart A, et al. Transcriptional downregulation of MHC class I and melanoma dedifferentiation in resistance to PD-1 inhibition. Nature Communications **2020**; in press.
- 43. Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, *et al.* Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One **2012**;7(12):e51862 doi 10.1371/journal.pone.0051862.

Figure Legends

Figure 1. High tumor CD155 expression limits response of metastatic melanoma patients to αPD1-combitherapy and predicts better RECIST response to BRAFi-targeted therapy.

(A) Representative immunohistochemistry images of CD155 H-scores (0+, 1+, 2+, 3+) from metastatic melanoma tumor specimens. (B) Histograms for CD155 Hscores by RECIST category (Complete Response [CR], Partial Response [PR], Stable Disease [SD], Progressive Disease [PD]) in pretreatment tumor specimens from metastatic melanoma patients treated with either α PD1-combitherapy (n = 64patients), α PD1-monotherapy (*n* = 87 patients), or BRAFi therapy (*n* = 41 patients). Fisher Exact Probability Test (FEPT) by CR+PR vs SD+PD and CD155^{low} (score 0+,1+,2+) vs CD155^{high} (score 3+). *P < 0.05; **P < 0.01; n.s. not significant. (C) The fraction of patients with progression free response to therapy greater than 6 months. FEPT by response > 6 months and response < 6 months vs CD155^{low} (score 0+, 1+, 2+) vs CD155^{high} (score 3+). **P < 0.01; n.s. not significant (D) Association of pretreatment tumor CD155 H-scores, CD155^{low} (0+,1+,2+) vs CD155^{high} (3+) with progression-free survival (PFS) evaluated using the Kaplan-Meier method and Cox proportional hazard modeling in melanoma patients treated with αPD1-monotherapy $(n = 57, \text{CD155}^{\text{low}}; n = 34, \text{CD155}^{\text{high}}; \text{HR} = 1.377; P = 0.26), \alpha \text{PD1-combitherapy} (n =$ = 45, CD155^{low}; n = 19, CD155^{high}; HR = 2.886; P = 0.007), or BRAFi therapy (n =25, CD155^{low}; n = 16, CD155^{high}; HR = 1.037; P = 0.9176).

Figure 2. Anti-PD1 therapy is ineffective in PDL1 negative melanomas that are high for CD155 expression and CD155 high tumors show decreased expression of critical genes involved in T cell function.

(A) Histograms of RECIST response categories (Complete Response [CR], Partial Response [PR], Stable Disease [SD], Progressive Disease [PD]) in metastatic melanoma by PDL1 status and CD155 tumor expression (CD155^{high} [3+] vs CD155^{low} [0+, 1+, 2+]) in pretreatment tumor specimens from metastatic melanoma patients treated with either α PD1-combitherapy (n = 38 patients) or α PD1monotherapy (n = 44 patients). Fisher Exact Probability Test (FEPT) by CR+PR vs SD+PD and PDL1^{negative}/CD155^{high} vs other scores. *P < 0.05; ***P < 0.001. (B) The fraction of patients with response > 6 months by PDL1 status and CD155 tumor expression. FEPT by response > 6 months vs response < 6 months and PDL1^{negative}/CD155^{high} vs other scores. **P < 0.01; n.s. not significant. (C) Progression free survival (PFS) of metastatic melanoma patients categorized by PDL1 status CD155 tumor expression. Association and between PDL1^{negative}/CD155^{high} vs other scores evaluated using Kaplan-Meier method. Patients were treated with either α PD1-monotherapy (n = 11, CD155^{low}/PDL1^{positive}; n $CD155^{high}/PDL1^{positive}$; n = 5, $CD155^{high}/PDL1^{negative}$; n = 17, 12. = CD155^{low}/PDL1^{negative}; HR = 2.391; P = 0.0584) or α PD1-combitherapy (n = 11, CD155^{low}/PDL1^{positive}; n = 3, CD155^{high}/PDL1^{positive}; n = 7, CD155^{high}/PDL1^{negative}; n = 717. $CD155^{low}/PDL1^{negative}$; HR = 6.117; P < 0.0001). (D) The top 20 enriched Reactome pathways from differential gene expression analysis (p-value < 0.01) of CD155 H-score 1+ vs 3+ melanomas. (E) Heatmap of genes which contribute to the Reactome pathway "Interferon signaling" (R-HSA-913531). Patients are clustered

according to CD155 H-score (from left to right: 0+, 1+, 2+, 3+) followed by PDL1 status (n = 41 patients).

Figure 3. Intratumor ratio of PD1⁺CD8⁺ T cells to total CD8⁺ T cells correlates with tumor CD155 levels.

(A) Representative multiplex-IF composite images of melanoma tumors with increasing CD155 score stained for CD8⁺ (red), PD1⁺ (green), and SOX10⁺ (light grey nuclei). White arrows indicate PD1⁺CD8⁺ lymphocytes. (B) Representative images for computational image analysis defining tissue category regions showing tumor parenchyma and tumor stroma with CD8⁺ T cells in tumor stroma indicated by red arrows and CD8⁺ T cells in tumor parenchyma indicated by white arrows. (C) Data summaries of total counts for tumor-infiltrating CD8⁺ lymphocytes (R = 0.130; P = 0.206), total PD1⁺CD8⁺ lymphocytes (R = 0.248; P = 0.015), and the ratio of PD1⁺CD8⁺ to total CD8⁺ lymphocytes (PD1^{tR}; R = 0.359; P < 0.0001), against CD155 H-score in pretreatment specimens from immunotherapy treated metastatic melanoma patients (n = 106 patients). (D) Validation of data in (C) using an independent cohort of patients treated with BRAFi therapy (n = 48 patients). Data summaries of total counts for tumor-infiltrating CD8⁺ lymphocytes (R = 0.095; P = 0.521), total PD1⁺CD8⁺ lymphocytes (R = 0.302; P = 0.037), and PD1^{tR} (R = 0.382; P < 0.007). Pearson correlation coefficient analyses were used (C and D) to assess the relationship between CD155 H-score and CD8⁺ T cells, PD1⁺CD8⁺ T cells, and PD1^{tR}. Exact *P* values and R coefficients have been included in each chart.

Figure 4. PD1^{tR} correlates with response to immunotherapy but not targeted therapy treated metastatic melanoma.

(A) Histogram of immunotherapy RECIST response categories (Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD)) from α PD1-combitherapy (n = 39), α PD1-monotherapy (n = 64), and BRAFi therapy (n = 39) treated metastatic melanoma patients. Fisher Exact Probability Test (FEPT) by CR+PR vs SD+PD and PD1^{IR}low vs PD1^{IR}high. **P < 0.01; ***P < 0.001; *n.s.* not significant. (B) The fraction of patients with therapy response greater than 6 months by PD1^{IR} measured in pretreatment tumor specimens. FEPT by response > 6 months vs response < 6 months and PD1^{IR}low vs PD1^{IR}high. **P < 0.01; n.s. not significant. (C) Association of pretreatment tumor PD1^{IR} with progression free survival (PFS) evaluated using the Kaplan-Meier method and Cox proportional hazard modeling in α PD1-combitherapy (n = 39; HR = 7.301; P = 0.0032), α PD1-monotherapy (n = 66; HR = 1.905; P = 0.094), and BRAFi therapy (n = 41; HR = 1.007; P = 0.9848), treated metastatic melanoma patients.

Declaration of Interests

Disclosures: MJS has research agreements with Bristol Myers Squibb, Aduro Biotech and Tizona Pharmaceuticals. MWLT has received speaker's honorarium from Roche, MSD, and BMS. WCD has received research funding from Bristol Myers Squibb and is a consultant for Omeros Corporation and Cascadia Drug Development Group. T.B. has research agreements with Bristol Myers Squibb and Ena Therapeutics and is member of the Scientific Advisory Board of Oncomyx. EA has speaker's honorarium from Amgen Australia, Conference/meeting travel/accommodation expenses or sponsorship from MSD, BMS, Roche, Amgen. GVL is consultant advisor to Aduro, Amgen, BMS, Merck MSD, Novartis, Roche. PAA is consultant advisor to BMS, Roche-Genentech, MSD, Array, Novartis, Merck Pierre Fabre, Incyte, Genmab, Newlink Genetics, Serono, Medimmune, Syndax. AstraZeneca. Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz. Immunocore, 4SC, Research Funds from BMS, Roche-Genentech, Array, Travel support from MSD. RAS has served on advisory boards for Merck Sharp Dohme, Glaxo Smith Kline Australia, Bristol Myers Squibb, Novartis Pharmaceuticals Australia, Myriad, Amgen, and NeraCare, unrelated to the content of this work. All other authors declare that they have no conflict of interest.

Financial support: A. L., J. M. and W. C. D. and some of the work were supported by a scientific research agreement from Bristol Myers Squibb and a project grant from the Australian Skin and Skin Cancer Research Centre. S. P. was supported by philanthropic funding from Terry Jackman. T. B. was supported by a National Health and Medical Research Council (NH&MRC) Early Career Research Fellowship (1138757). M. W. L. T. was supported by a NH&MRC Career Development Fellowship (1159655) and Project Grant (1120887). M. J. S. was supported by a NH&MRC Senior Principal Research Fellowship (1078671), a NH&MRC Program Grant (1132519) and a CCQ Project Grant (1157048). For R. A. S. some of this work was supported by a NHMRC Program Grant (G. V. L & R. A. S.) and the NHMRC Fellowship program (J. S. W., G. V. L. & R. A. S.). Funding support from Melanoma Institute Australia (MIA) and The Ainsworth Foundation is also gratefully acknowledged. The authors also thank colleagues at Royal Prince Alfred Hospital and MIA for assistance.



Downloaded from clincancerres.aacrjournals.org on October 23, 2020. © 2020 American Association for Cancer Research.



Downloaded from clincancerres.aacrjournals.org on October 23, 2020. © 2020 American Association for Cancer Research.





Table 1 – Specimen cohort details

	[MIA] melanoma	[RBWH] melanoma	[INT-IRCCS] melanoma	[PG-XXIII] melanoma
Specimen details				
<i>n</i> =	101	33	21	50
Sex				
female	24	8	9	23
male	62	25	12	27
unknown	15			
Median age (start of IO)	67	68	64	54
Surgery type				
excision	101	25	21	50
biopsy		8		
Multiplex-IF data	yes	yes	no	yes
Tissue microarray	yes	yes	no	yes
Therapy details				·
Nivolumab	16		7	
Pembrolizumab	33	29	3	
lpi + Nivo	18	4	8	
Ipi + Pembro	34		3	
, 1st line BRAFi targeted therapy	7	6	2	41
Clinically reported variables				
BRAF mutant	22	7	6	50
BRAF wild type	60	26	15	
LDH elevated	16		10	
LDH normal	63		10	
RECIST response			-	
	00	10	40	
PD	22	10	10	9
PR	42	6	3	16
SD	6	4	1	8
CR	28	11	1	8
no data	3	2		
Progression summary				
# censored subjects	64	16	3	8
# events (progression)	37	17	18	33
Median PFS (years)	4.83	0.82	0.42	1.03
Median follow-up	1.38	0.63	0.41	1.56
Survival summary				
# censored subjects	75	19	5	10
# events (death)	26	14	16	31
Median OS (years)	undefined	undefined	0.833	1.85
Median follow-up	1.68	1.44	0.82	2.14
CD155 H-Score				
0+(0)	7	0	3	0
1+ (1 - 99)	23	7	4	11
2+ (100 - 199)	35	14	9	17
3+ (200 - 300)	36	12	5	22



Clinical Cancer Research

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

Ailin Lepletier, Jason Madore, Jake S O'Donnell, et al.

Clin Cancer Res Published OnlineFirst April 28, 2020.

Updated version	Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-19-3925
Supplementary Material	Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2020/04/28/1078-0432.CCR-19-3925.DC1
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2020/04/28/1078-0432.CCR-19-3925. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.